European Radiology · 11 Nov 2026
Commercially available AI medical devices for prostate MRI: current evidence and opportunities for implementation
Jina Pakpoor, Yasin Bhanji, Kicky G. van Leeuwen, Iztok Caglic, Natasha Thorley, Max Whittaker, Mark Emberton, Caroline M. Moore, Veeru Kasivisvanathan, Louise Dickinson, Shonit Punwani, Clare Allen, Alexander Kirkham, Douglas Pendse, Maarten de Rooij, Giorgio Brembilla, Francesco Gigantih-index 35
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Objective Artificial intelligence (AI) may improve prostate MRI interpretation and reduce radiologist workload, but evidence supporting clinical implementation remains limited. This scoping review summarises evidence on commercially available AI medical devices for prostate MRI. Materials and methods PubMed was searched for studies published through October 1, 2026. Eligible devices were cleared by the United States Food and Drug Administration and/or CE marked, with commercial availability corroborated through manufacturer websites. Data extraction addressed standalone AI performance, AI-assisted radiologist performance, workflow efficiency, and downstream clinical impact. Results Twenty-one studies evaluating 7 commercial AI systems were included; 17/21 (81%) were retrospective and 14/21 (67%) were single-centre. AI assistance suggested greater benefit for less-experienced readers, but improvements were inconsistent and increased specificity sometimes accompanied reduced sensitivity. Standalone evaluations, outside the devices’ approved intended use, showed discrimination comparable to that of radiologists in selected cohorts. Inter-reader agreement and workflow benefits were mixed. We identify three key limitations of the current body of evidence that require thoughtful consideration before routine implementation: (1) incomplete verification strategies, (2) limited determination of workflow benefit, and (3) lack of analyses of cost-effectiveness and patient outcomes, e.g., time to treat or cancer-free survival. Conclusion Evidence supporting the use of commercial AI for prostate MRI remains limited and heterogeneous, with inconsistent diagnostic benefits. Prospective comparative studies in real clinical workflows are needed to determine its potential role within the prostate cancer diagnostic pathway. Key Points Question Evidence for clinical implementation of prostate AI remains limited—most studies are retrospective and single-centre, with heterogeneous populations and reference standards. Findings AI may improve diagnostic performance for less-experienced readers, but gains for expert readers and assessment of workflow efficiency are limited. Clinical relevance Prospective multicentre studies embedded in real-world pathways are needed, together with analyses of cost-effectiveness and patient outcomes .
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Francesco Giganti has the highest h-index among the authors (35).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (40)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 20 more references
A free account opens the rest of the citing papers and references on every paper’s page.